Fluarix Quadrivalent Vaccine Shipment Commences
The FDA has approved GlaxoSmithKline to start shipping Fluarix Quadrivalent influenza vaccine to CDC distribution centers and U.S. healthcare providers for the 2013–2014 influenza season. This is the first season that vaccines protecting against >3 strains of influenza will be commercially available.
Fluarix Quadrivalent is an intramuscular vaccine indicated for influenza immunization in patients >3 years old. Fluarix Quadrivalent protects against four strains of influenza (subtypes A and B), which differs from most current influenza vaccines that provide three-strain influenza protection.
For this season's shipments, GlaxoSmithKline will supplement the supply of Fluarix Quadrivalent with its trivalent season influenza vaccines. In the coming years, GlaxoSmithKline will increase its capability to provide more quadrivalent influenza vaccines.
For more information call (888) 825-5249 or visit Fluarix.com.